Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19.

McAdams MC, Xu P, Saleh SN, Li M, Ostrosky-Frid M, Gregg LP, Willett DL, Velasco F, Lehmann CU, Hedayati SS. Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19. Kidney medicine. 2022 Jun 1; 4(6):100463.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

RATIONALE and OBJECTIVE: Acute kidney injury (AKI) is common in patients hospitalized with COVID-19, but validated, predictive models for AKI are lacking. We aimed to develop the best predictive model for AKI in hospitalized patients with coronavirus disease 2019 and assess its performance over time with the emergence of vaccines and the Delta variant. STUDY DESIGN: Longitudinal cohort study. SETTING and PARTICIPANTS: Hospitalized patients with a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction result between March 1, 2020, and August 20, 2021 at 19 hospitals in Texas. EXPOSURES: Comorbid conditions, baseline laboratory data, inflammatory biomarkers. OUTCOMES: AKI defined by KDIGO (Kidney Disease: Improving Global Outcomes) creatinine criteria. ANALYTICAL APPROACH: Three nested models for AKI were built in a development cohort and validated in 2 out-of-time cohorts. Model discrimination and calibration measures were compared among cohorts to assess performance over time. RESULTS: Of 10,034 patients, 5,676, 2,917, and 1,441 were in the development, validation 1, and validation 2 cohorts, respectively, of whom 776 (13.7%), 368 (12.6%), and 179 (12.4%) developed AKI, respectively (  =  0.26). Patients in the validation cohort 2 had fewer comorbid conditions and were younger than those in the development cohort or validation cohort 1 (mean age, 54 ± 16.8 years vs 61.4 ± 17.5 and 61.7 ± 17.3 years, respectively,   <  0.001). The validation cohort 2 had higher median high-sensitivity C-reactive protein level (81.7 mg/L) versus the development cohort (74.5 mg/L;   <  0.01) and higher median ferritin level (696 ng/mL) versus both the development cohort (444 ng/mL) and validation cohort 1 (496 ng/mL;   <  0.001). The final model, which added high-sensitivity C-reactive protein, ferritin, and D-dimer levels, had an area under the curve of 0.781 (95% CI, 0.763-0.799). Compared with the development cohort, discrimination by area under the curve (validation 1: 0.785 [0.760-0.810],   =  0.79, and validation 2: 0.754 [0.716-0.795],   =  0.53) and calibration by estimated calibration index (validation 1: 0.116 [0.041-0.281],   =  0.11, and validation 2: 0.081 [0.045-0.295],   =  0.11) showed stable performance over time. LIMITATIONS: Potential billing and coding bias. CONCLUSIONS: We developed and externally validated a model to accurately predict AKI in patients with coronavirus disease 2019. The performance of the model withstood changes in practice patterns and virus variants.